Royal London Asset Management Ltd. Makes New $5.01 Million Investment in Revvity, Inc. (NYSE:RVTY)

Royal London Asset Management Ltd. bought a new stake in shares of Revvity, Inc. (NYSE:RVTYFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 45,862 shares of the company’s stock, valued at approximately $5,013,000.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. purchased a new position in shares of Revvity in the third quarter valued at about $1,579,487,000. Capital Research Global Investors bought a new position in Revvity in the 4th quarter worth approximately $838,080,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Revvity during the fourth quarter worth $188,368,000. Norges Bank purchased a new position in shares of Revvity during the fourth quarter valued at about $129,483,000. Finally, Northern Trust Corp purchased a new stake in shares of Revvity in the fourth quarter worth about $127,401,000. Institutional investors own 86.65% of the company’s stock.

Revvity Trading Down 1.9 %

Shares of NYSE:RVTY traded down $2.07 during trading hours on Friday, hitting $108.65. 1,078,325 shares of the company’s stock traded hands, compared to its average volume of 967,166. The firm has a market capitalization of $13.41 billion, a P/E ratio of 89.79, a price-to-earnings-growth ratio of 2.83 and a beta of 1.08. The business has a fifty day moving average price of $106.69 and a 200-day moving average price of $105.19. Revvity, Inc. has a 1 year low of $79.50 and a 1 year high of $131.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92.

Revvity (NYSE:RVTYGet Free Report) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.94 by $0.04. The company had revenue of $649.90 million for the quarter, compared to the consensus estimate of $646.83 million. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 EPS. Equities analysts expect that Revvity, Inc. will post 4.65 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. Revvity’s payout ratio is 23.14%.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the completion of the sale, the insider now directly owns 36,900 shares in the company, valued at approximately $4,075,974. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on RVTY shares. Jefferies Financial Group started coverage on Revvity in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price for the company. Robert W. Baird upped their target price on shares of Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research report on Tuesday, April 30th. Finally, TD Cowen lifted their price target on Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Revvity presently has a consensus rating of “Moderate Buy” and an average target price of $117.92.

Get Our Latest Analysis on RVTY

About Revvity

(Free Report)

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

See Also

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTYFree Report).

Institutional Ownership by Quarter for Revvity (NYSE:RVTY)

Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.